Dialyzable leukocyte extract
Also known as: DLE, Immodin, Leukocyte dialysate, Transfer Factor, Transferon
Source Dialyzable leukocyte extract at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Dialyzable leukocyte extract (DLE), also called transfer factor, is a prescription‑only mixture of low‑molecular‑weight peptides derived from leukocyte filtrates. It is marketed as an immunomodulatory agent and has been investigated as an adjunct in conditions such as chronic fatigue syndrome, human papillomavirus‑related cervicitis, allergic rhinitis, and certain infections. The product can be administered intravenously, subcutaneously, or orally.
Mechanism of Action
Transfer factor is thought to act on cell‑mediated immunity. In vitro and animal studies suggest it stimulates production of migration‑inhibitory factor and interferon‑γ while inhibiting NF‑κB signaling, leading to reduced secretion of pro‑inflammatory cytokines such as TNF‑α and IL‑4. These actions collectively modulate innate and adaptive immune responses, although the precise molecular composition remains undefined.
What the Research Shows
A double‑blind, placebo‑controlled trial in chronic fatigue syndrome (90 participants) found no specific benefit of DLE alone or combined with cognitive‑behavioral therapy. In a randomized study of 54 women with HPV‑associated chronic cervicitis, DLE led to clinical remission in 89% of treated patients, reduced leukocyte infiltrates, increased TGF‑β and decreased IFN‑γ, PCNA, and IL‑32 in cervical tissue. An uncontrolled prospective trial in 30 adults with moderate‑to‑severe allergic rhinitis reported significant improvements in quality‑of‑life scores after oral DLE supplementation. A Cochrane review on cryptosporidiosis noted a single bovine DLE study showing a non‑significant trend toward reduced stool frequency. Overall, evidence consists of small, heterogeneous trials with limited replication.
Reported Benefits
The most consistent positive findings come from the HPV‑related cervicitis study, where DLE reduced clinical lesions and altered local cytokine profiles, suggesting enhanced mucosal immunity. Preliminary data from an allergic rhinitis cohort indicate potential quality‑of‑life improvement when added to standard therapy. A single cryptosporidiosis trial hinted at decreased diarrhoeal frequency, though statistical significance was not achieved. These benefits are supported by limited, early‑phase research and require confirmation in larger, controlled studies.
Limitations of the Evidence
Most investigations are small, lack blinding, or are uncontrolled, limiting confidence in efficacy. The chronic fatigue syndrome trial showed no effect, highlighting condition‑specific variability. Dosing regimens differ widely (oral versus injectable, varying amounts), and the antigen‑specific versus non‑specific nature of the extract remains unclear. The paucity of large, multicenter randomized trials and inconsistent outcomes across indications constitute major gaps.
Safety Considerations
Published trials did not report serious adverse events, and DLE is generally regarded as well tolerated. However, safety data are limited to short‑term studies with small cohorts, and long‑term or rare side‑effects have not been systematically evaluated. Caution may be warranted in severely immunocompromised patients until more robust safety information is available.
How It Is Administered
DLE is supplied as a peptide mixture that can be given intravenously, subcutaneously, or orally, depending on the formulation. Clinical studies have used injectable preparations as well as oral tablets or capsules, typically administered in low‑milligram daily or weekly regimens, though exact dosing varies across trials.
Routes of Administration
Goals & Uses
- Adjunctive cancer immunotherapyOncologyLow
- Adjunctive therapy in tuberculosisInfectious DiseaseLow
- Recurrent respiratory tract infectionsImmunomodulation / Infection PreventionModerate
- Atopic dermatitis / allergic conditionsDermatology / AllergyLow
- Adjunctive therapy in primary immunodeficiencyImmunodeficiencyModerate
- Adjunctive treatment in herpetic infectionsAntiviral / ImmunomodulationModerate
Contraindications
- Autoimmune diseasesImmunologicalHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Organ transplant recipients on immunosuppressionTransplantHigh
- Known hypersensitivity to DLE or bovine proteinsAllergyHigh
Adverse Effects
- Allergic reactionsImmunologicalRare
- Autoimmune exacerbationImmunologicalRare
- Injection site reactionsLocalCommon
- Gastrointestinal discomfortGastrointestinalUncommon
- Fever / flu-like symptomsSystemicUncommon
Drug Interactions
- Biologic immunomodulators (TNF inhibitors, anti-IL agents)Moderate
- Live vaccinesLow
- Immunosuppressants (corticosteroids, cyclosporine, tacrolimus)Moderate
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveRelative
- Elderly patientsAgeRelative
- Patients with active autoimmune diseaseImmunologicalRelative
Regulatory Status
- European UnionUnknownApproved in some Eastern European countries (e.g., Czech Republic as Immodin); not centrally approved by EMA. Status varies by member state.
- United StatesUnapprovedNot FDA-approved as a drug. Bovine transfer factor sold as dietary supplement but not recognized as a pharmaceutical. Research use only in clinical settings.
- United KingdomUnknownNot approved by MHRA as a licensed medicine. No current marketing authorization in the UK.
Approved and marketed in Mexico (as Transferon) for recurrent respiratory infections and as an immunomodulator. Approved in Cuba and some Eastern European countries. Not approved by the FDA in the US; classified as a research/investigational agent in the US and EU. OTC transfer factor supplements (typically bovine-derived) are sold in the US but are not FDA-approved drugs.
Evidence & Sources
- Journal ArticleModerateLloyd AR, et al.1993-01-01T00:00:00.000000Z
- Journal ArticleModerateMacias AE, Guaní-Guerra E2020-01-01T00:00:00.000000Z
- Journal ArticleHighAbubakar I, et al.2007-01-01T00:00:00.000000Z
- Journal ArticleModerateAcosta-Rios MP, et al.2017-01-01T00:00:00.000000Z
- Journal ArticleModerateHomberg TA, et al.2023-01-01T00:00:00.000000Z
- Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictionsJournal ArticleModerateLarenas-Linnemann D, et al.2020-01-01T00:00:00.000000Z
Frequently Asked Questions
What conditions has dialyzable leukocyte extract been studied for?
It has been evaluated in chronic fatigue syndrome, HPV‑related cervical lesions, allergic rhinitis, and as an adjunct in cryptosporidiosis, among other infectious or immune‑mediated disorders.
Is DLE approved for any specific medical use?
The product is listed as an approved prescription medication, but the abstracts do not indicate regulatory approval for a particular indication; its use remains largely investigational.
How is DLE thought to influence the immune system?
Research suggests DLE promotes interferon‑γ and migration‑inhibitory factor production, while suppressing NF‑κB‑driven cytokines like TNF‑α and IL‑4, thereby modulating both innate and adaptive immunity.
Are there any known side effects of DLE?
Published studies have not reported significant adverse events, but safety information is limited to short‑term, small‑scale trials, so rare or long‑term effects are not well characterized.
Can DLE be taken orally, or does it require injection?
Both routes have been used; oral tablets or capsules and injectable formulations (intravenous or subcutaneous) have been described in clinical investigations.
What is Dialyzable leukocyte extract?
Dialyzable leukocyte extract (DLE), also called transfer factor, is a prescription‑only mixture of low‑molecular‑weight peptides derived from leukocyte filtrates. It is marketed as an immunomodulatory agent and has been investigated as an adjunct in conditions such as chronic fatigue syndrome, human papillomavirus‑related cervicitis, allergic rhinitis, and certain infections. The product can be administered intravenously, subcutaneously, or orally.
What is Dialyzable leukocyte extract used for?
Dialyzable leukocyte extract is educationally associated with: Adjunctive cancer immunotherapy, Adjunctive therapy in tuberculosis, Recurrent respiratory tract infections, Atopic dermatitis / allergic conditions, Adjunctive therapy in primary immunodeficiency, Adjunctive treatment in herpetic infections. Educational only — not medical advice.
How is Dialyzable leukocyte extract administered?
Recorded routes of administration: Intravenous, Oral, Subcutaneous.
What are the potential side effects of Dialyzable leukocyte extract?
Reported adverse effects include: Allergic reactions, Autoimmune exacerbation, Injection site reactions, Gastrointestinal discomfort, Fever / flu-like symptoms. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dialyzable leukocyte extract?
Recorded contraindications: Autoimmune diseases, Pregnancy, Organ transplant recipients on immunosuppression, Known hypersensitivity to DLE or bovine proteins. Consult a qualified clinician before use.